Two days to proxy votes, and IMHOs.
(1)Yesterday's dive driven by algorithms responding to Amended S1 posted after hours on Friday. On the original S1 posting, 19 Sept, we crashed 10% after hours. SSDD.
(2)Thinking both proposals are going to pass on Halloween, then reverse split put off till December 31st (Happy New Years).
Asking Sanjay for firm information on our LineaRX collaborations. We know of only 3. Two are Veternary
(1)&(2)Takis & Evvivax, Veternary, Italy, no drug trials found
(3d) Collaboration LINK to Prostate Cancer Collaboration with Tyme.
Announced 1st of October. Note the three year study dates and limited participants (25). LineaRX is only a year old (more or less). So we weren't COLLABORATORs till more recently than start of study. May be our FIRST, and reason to spin off our subsidiary. Dunno.[/quote]In Tyme collaboration LineaRX used in diagnostic tests of patient's blood to find and track changing levels of invasive Circulating Tumor Cells (iCTCs). In prostate cancer, elevated Prostate-Specific Antigen (PSA) levels are tracked.
A little bit on tracking antigens or any trace of cancer for pancreatic cancer hasn't been found. This cancer somehow hides invasive Circulating Tumor Cells (iCTCs) somehow. Here's data on Tyme's clinical trial in place. AND, we are NOT listed as a collaborator with them anywhere. My long shot here.
ClinicalTrials.gov Identifier: NCT03512756
Official Title:A Randomized Phase 2/3 Multi-Center Study of
SM-88 in Subjects With Pancreatic Cancer
Whose Disease Has Progressed or Recurred
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Actual Study Start Date : March 27, 2018
Est Primary Compl Date : December 31, 2020
Est Study Comp Date : December 31, 2020
[/quote]
LINK to Clinical Trials.gov
Link to Pancreatic Cancer Action Network Trial
My opinions, nuthing more. GLTUA
